To convert the meeting times to your local time Click Here
Industry Hall 2
A previous assessment of global access to hereditary predisposition testing including BRCA1 and BRCA2 identified significant variability in guidelines and implementation. Exploration of potential solutions led to the development of standardized risk assessment and testing pathways in two key European countries. This session will outline the steps taken to enhance patient access and demonstrate improved outcomes over time.